Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🇷🇴 RO Market
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Industry
Any
Automobiles
Banks
Capital Goods
Commercial Services
Consumer Durables
Consumer Services
Diversified Financials
Energy
Consumer Retailing
Food, Beverage & Tobacco
Healthcare
Household
Insurance
Materials
Media
Pharmaceuticals & Biotech
Real Estate
Retail
Semiconductors
Software
Tech
Telecom
Transportation
Utilities
Create a narrative
Community
/
Romania
Romanian Market Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Romanian Investing Ideas
Global Weekly Picks
Hoth Therapeutics
Sponsored
content by Hoth Therapeutics
JO
Jolt_Communications
Community Contributor
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
View narrative
US$5.30
FV
72.3% undervalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
2
users have commented on this narrative
63
users have followed this narrative
Updated
narrative
Exxon Mobil
HE
Helzur
Community Contributor
Exxon Mobil's 17.5% Upside Promises Industry-Leading Returns in Energy Transition
This analysis concludes that Exxon Mobil (XOM) represents a compelling investment opportunity, with a fair value of $132.00 per share, implying a 17.5% upside from the current price of $112.32. The BUY recommendation is not based on a speculative bet on higher oil prices, but on the company's fundamental transformation, operational excellence, and disciplined capital allocation that is expected to generate sustainable, industry-leading returns.
View narrative
US$132.00
FV
16.8% undervalued
intrinsic discount
6.50%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
8 days ago
author updated this narrative
National HealthCare
DA
DanielGC
Community Contributor
NHC Analysis: Quality at a Good Price. A Golden Opportunity?
Key Takeaways A highly diversified business model and a pristine balance sheet position National HealthCare Corporation for sustained, profitable growth. The company's current low valuation is a result of a short-term drop in net income, which we believe is temporary and creates a compelling investment opportunity.
View narrative
US$179.80
FV
35.5% undervalued
intrinsic discount
18.80%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
21 days ago
author updated this narrative
lululemon athletica
AN
AnalystConsensusTarget
Consensus Narrative from 29 Analysts
New Product Lines And Store Expansion Will Fuel Global Momentum
Key Takeaways Global expansion and product innovation targets high-growth markets to drive revenue, enhance brand awareness, and improve customer acquisition and retention. Physical store expansion and community-based activations aim to boost market presence, guest loyalty, and sustain long-term growth despite macroeconomic challenges.
View narrative
US$270.82
FV
37.9% undervalued
intrinsic discount
6.34%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
137
users have followed this narrative
6 days ago
author updated this narrative
All companies
Popular
Undervalued
Overvalued
There are no community narratives available.
Value any company in seconds
Popular companies